{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:15:31Z","timestamp":1778260531638,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with impact on axial skeleton, peripheral joints and enthuses, and it may result in severe disabilities of those parts. Tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors are considered as an effective treatment for patients with active AS. In this study, we conducted a network meta-analysis to compare the clinical outcomes of active AS patients treated with TNF-\u03b1 inhibitors. Randomized controlled trials (RCTs) evaluating the efficacy and safety of TNF-\u03b1 inhibitors were retrieved in literature search and selected for meta-analysis. Changes in ASAS20 response, ASAS40 response and BASDAI 50% response were regarded as efficacy outcomes; serious adverse events (SAE) and all cause withdrawals were regarded as safety outcomes. Both traditional pairwise meta-analysis and network meta-analysis were performed. The results showed that adalimumab and infliximab had better clinical outcomes. Infliximab consistently appeared to be the most effective TNF-\u03b1 inhibitors with a high risk of adverse events for patients with active AS; meanwhile, adalimumab ranked highest with respect to adverse effects with efficacy secondary to infliximab. As a result, we were unable to conclude the optimal TNF-\u03b1 inhibitor and this issue should be solved by future researchers.<\/jats:p>","DOI":"10.1038\/srep32768","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T09:33:40Z","timestamp":1474882420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and safety of TNF-\u03b1 inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis"],"prefix":"10.1038","volume":"6","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bin Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bin Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"BFsrep32768_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun, J. & Sieper, J. Ankylosing spondylitis. The Lancet 369, 1379\u20131390 (2007).","journal-title":"The Lancet"},{"key":"BFsrep32768_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","volume":"48\u201349","author":"SP Raychaudhuri","year":"2014","unstructured":"Raychaudhuri, S. P. & Deodhar, A. The classification and diagnostic criteria of ankylosing spondylitis. Journal of Autoimmunity 48\u201349, 128\u2013133 (2014).","journal-title":"Journal of Autoimmunity"},{"key":"BFsrep32768_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick, C. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58, 15\u201325 (2008).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/BF03342637","volume":"15","author":"MA Khan","year":"1996","unstructured":"Khan, M. A. Epidemiology of HLA-B27 and arthritis. Clinical rheumatology 15, 10\u201312 (1996).","journal-title":"Clinical rheumatology"},{"key":"BFsrep32768_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"SVD Linden","year":"1984","unstructured":"Linden, S. V. D., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis & Rheumatism 27, 361\u2013368 (1984).","journal-title":"Arthritis & Rheumatism"},{"key":"BFsrep32768_CR6","first-page":"CD005468","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell, L. J. et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4, CD005468 (2015).","journal-title":"Cochrane Database Syst Rev"},{"key":"BFsrep32768_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling, J. et al. ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 65, 442\u2013452 (2006).","journal-title":"Annals of the Rheumatic Diseases"},{"key":"BFsrep32768_CR8","doi-asserted-by":"crossref","unstructured":"Sieper, J. & Braun, J. Management of ankylosing spondylitis. In: Ankylosing Spondylitis. Springer, p 49\u201372 (2011).","DOI":"10.1007\/978-0-85729-180-6_6"},{"key":"BFsrep32768_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","volume":"39","author":"K Knobloch","year":"2011","unstructured":"Knobloch, K., Yoon, U. & Vogt, P. M. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 39, 91\u201392 (2011).","journal-title":"J Craniomaxillofac Surg"},{"key":"BFsrep32768_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR11","unstructured":"Higgins, J. P. T. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration (2011)."},{"key":"BFsrep32768_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti, G., Ades, A. E. & Ioannidis, J. P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64, 163\u2013171 (2011).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep32768_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang, F. et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73, 587\u2013594 (2014).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao, C. et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford) 53, 1654\u20131663 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32768_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados, M. et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70, 799\u2013804 (2011).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman, R. D. & Maksymowych, W. P. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37, 1203\u20131210 (2010).","journal-title":"J Rheumatol"},{"key":"BFsrep32768_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans, B. et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36, 1256\u20131264 (2009).","journal-title":"J Rheumatol"},{"key":"BFsrep32768_CR18","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman, R. D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58, 3402\u20133412 (2008).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54, 2136\u20132146 (2006).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Etanercept 50\u2009mg once weekly is as effective as 25\u2009mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65, 1572\u20131577 (2006).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52, 582\u2013591 (2005).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR22","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega, H. et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64, 1568\u20131575 (2005).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin, A. et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63, 1594\u20131600 (2004).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt, J. et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63, 1438\u20131444 (2004).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32768_CR25","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr.","year":"2003","unstructured":"Davis, J. C. Jr. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48, 3230\u20133236 (2003).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt, J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48, 1667\u20131675 (2003).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32768_CR27","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman, J. D., Sack, K. E. & Davis, J. C. Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346, 1349\u20131356 (2002).","journal-title":"N Engl J Med"},{"key":"BFsrep32768_CR28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun, J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359, 1187\u20131193 (2002).","journal-title":"Lancet"},{"key":"BFsrep32768_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344, 907\u2013916 (2001).","journal-title":"N Engl J Med"},{"key":"BFsrep32768_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun, J. et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis & Rheumatism 38, 499\u2013505 (1995).","journal-title":"Arthritis & Rheumatism"},{"key":"BFsrep32768_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt, M. E. et al. Adalimumab, a fully human anti\u2013tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis & Rheumatism 48, 35\u201345 (2003).","journal-title":"Arthritis & Rheumatism"},{"key":"BFsrep32768_CR32","doi-asserted-by":"crossref","unstructured":"Keystone, E. C. et al. Golimumab, a human antibody to TNF-\u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD Study. Annals of the rheumatic diseases (2008).","DOI":"10.1136\/ard.2008.099010"},{"key":"BFsrep32768_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 340, 253\u2013259 (1999).","journal-title":"New England Journal of Medicine"},{"key":"BFsrep32768_CR34","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet 354, 1932\u20131939 (1999).","journal-title":"The Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32768","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:50:50Z","timestamp":1672876250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep32768"],"URL":"https:\/\/doi.org\/10.1038\/srep32768","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]},"assertion":[{"value":"7 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32768"}}